Manipulating thymic apoptosis for future therapy of autoimmune diseases

Current Pharmaceutical Design

Volumn 17, Issue 29, 2011, Pages 3108-3119

  Delfino, Domenico V ^a   Pozzesi, Nicola ^a   Pierangeli, Sara ^a   Ayroldi, Emira ^a   Fierabracci, Alessandra ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Apoptosis; Autoimmunity; Glucocorticoids; Negative selection; Thymus

Indexed keywords

CASPASE; CD4 ANTIGEN; CD8 ANTIGEN; GLUCOCORTICOID;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELL INTERACTION; CELL MATURATION; DRUG TARGETING; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; NEGATIVE SELECTION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; THYMOCYTE; THYMUS;

ANIMALS; APOPTOSIS; AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; HUMANS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; THYMOCYTES; THYMUS GLAND;

EID: 80055089042     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798157621     Document Type: Article

References (169)

1. Werlen G, Hausmann B, Naeher D, Palmer E. Signaling life and death in the thymus: timing is everything. Science 2003; 299: 1859-63.
2. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol 2003; 21: 139-76.
3. Van Ewijk W, Hollander G, Terhorst C, Wang B. Stepwise development of thymic microenvironments in vivois regulated by thymocyte subsets. Development 2000; 127: 1583-91.
4. Anderson G, Moore NC, Owen JJT, Jenkinson EJ. Cellular interactions in thymocyte development. Annu Rev Immunol 1996, 14: 73-99
5. Carlyle JR, Zuniga-Pflucker JC. Requirement for the thymus in alpha-beta T lymphocyte lineage commitment. Immunity 1998, 9: 187-97.
6. Cordier AC, Haumont SM. Development of the thymus, parathyroids, and ultimobranchial bodies in NMRI and nude mice. Am J Anat 1980, 157: 227-63.
7. Nehls M, Kyewski B, Messerle M, Waldschutz R, Schuddekopf K, Simth AJH, Boehm T. Two genetically separable steps in the differentiation of thymic epithelium. Science 1996, 272: 886-9.
8. Von Boehmer H. The developmental biology of T lymphocytes. Annu Rev Immunol 1993, 6: 309-26.
9. Akashi K, Kondo M, Cheshier S, et al. Lymphoid development from stem cells and the common lymphoid progenitors. Cold Spring Harbor Symp Quant Biol 1999, 64: 1-12.
10. Shortman K, Egerton M, Spangrude GJ, Scollay R. The generation and fate of thymocytes. Semin Immunol 1990, 2: 3-12.
11. Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 1994, 372: 100-3.
12. th edition. 2005 Garland Science publishing
13. Godfrey DI, Purton JF, Botd RL, Cole TJ. Stress-free T-cell development: glucocorticoids are not obligatory. Immunol Today 2000; 21: 606-11.
14. Borowski C, Martin C, Gounari F, Haughn L, Aifantis I, Grassi F, von Boehmer H. On the brink of becoming a T cell. Curr Opin Immunol 2002; 14: 200-6.
15. Saint-Ruf C, Ungewiss K, Groetrrup M, Bruno L, Fehling HJ, von Boehmer H. Analysis and expression of a cloned pre-T-cell receptor gene. Science 1994, 266: 1208-12.
16. Shortman K, Wu L. Early T lymphocyte progenitors. Annu Rev Immunol 1996: 14: 29-47.
17. Cohen O, Kfir-Erenfeld, Spokoini R, Zilberman Y, Yefenof E, Sionov RV. Nitric oxide cooperates with glucocorticoids in thymic epithelial cell-mediated apoptosis of double positive thymocytes. Int Immunol 2009; 21: 1113-23.
18. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol 2000; 18: 309-45.
19. Brewer JA, Kanagawa O, Sleckman BP, Muglia LJ. Thymocyte apoptosis induced by T cell activation is mediated by glucocorticoids in vivo. J Immunol 2002; 169: 1837-43.
20. Bouillet P, Metcalf D, Huang DC, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999, 286: 1735-8.
21. Rathmell JC, Lindsten T, Zong WX, Cinalli RM, Thompson CB. Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol 2002; 3: 932-9.
22. Marsden VS, O'Connor L, O'Really LA, et al. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 2002; 419: 634-7.
23. King LB, Vacchio MS, Ashwell JD, To be or not to be: mutually antagonistic death signals regulate thymocyte apoptosis. Int Arch Allergy Immunol. 1994; 105: 355-8.
24. Erlacher M, Knoflach M, Stec IE, Bock G, Wick G, Wiegers GJ. TCR signaling inhibits glucocorticoid-induced apoptosis in murine thymocytes depending on the stage of development. Eur J Immunol. 2005; 35: 3287-96
25. Marchetti MC, Di Marco B, Cifone G, Migliorati G, Riccardi C, Dexamethasone-induced apoptosis of thymocytes: role of glucocorticoid receptor-associated Src kinase and caspase-8 activation. Blood. 2003; 101: 585-93.
26. Cifone MG, Migliorati G, Parroni R, et al. Dexamethasone-induced thymocyte apoptosis: apoptotic signal involves the sequential activation of phosphoinositide-specific phospholipase C, acidic sphingomyelinase, and caspases. Blood. 1999; 93: 2282-96
27. D'Adamio F, Zollo O, Moraca R, et al. A new dexamethasoneinduced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity. 1997; 7: 803-12
28. Cannarile L, Zollo O, D'Adamio F, et al. Cloning, chromosomal assignment and tissue distribution of human GILZ, a glucocorticoid-induced gene. Cell Death Differ. 2001; 8: 201-3
29. Asselin-Labat ML, David M, Biola-Vidamment A, et al. GILZ, a new target for the transcription factor FoxO3, protects T lymphocytes from interleukin-2 withdrawal-induced apoptosis. Blood. 2004; 104: 215-23
30. Wang JC, Derynck NK, Nonaka DF, Khodabackhsh DB, Happ C, Yamamoto KR. Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc Natl Acad Sci U.S.A. 2004; 101: 15603-8.
31. Tynan SH, Lundeen SG, Allan GF. Cell type-specific bidirectional regulation of the glucocorticoid-induced leucine zipper (GILZ) gene by estrogen. J Steroid Biochem Mol Biol. 2004; 91: 225-39
32. Asselin-Labat ML, Biola-Vidamment A, Kerbrat S, Lombes M, Bertoglio J, Pallardy M. FoxO3 mediates antagonistic effects of glucocorticoids and interleukin-2 on glucocorticoid-induced leucine zipper expression. Mol Endocrinol. 2005; 19: 1752-64.
33. Chen W, Rgatsky I, Garabedan MJ. MED14 and MD1 dfferenall reglate target-specfic gene actvaton by the glcocorticod receptor. Mol Endocrnol. 2006; 20: 560-72
34. Van der Laan S, Sarabdjitsingh RA, Van Batenburg MF, et al. Chromatin immunoprecipitation scanning identifies glucocorticoid receptor binding regions in the proximal promoter of a ubiquitously expressed glucocorticoid target gene in brain. J Neurochem. 2008; 106: 2515-23
35. Ayroldi E, Migliorati G, Bruscoli S, et al. Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor-B. Blood. 2001; 98: 743-53.
36. Delfino DV, Agostini M, Spinicelli S, Vito P, Riccardi C, Decrease of Bcl-xL expression and augmentation of apoptosis in GILZ-overexpressing transgenic mice. Blood 2004; 104: 4134-41.
37. Ayroldi E, Zollo O, Bastianelli A, et al. GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J Clin Invest. 2007; 117: 1605-15.
38. Cannarile L, Fallarino F, Agostini M, et al. Increased Gilz expression in transgenic mice up-regulates Th-2 lymphokines. Blood. 2006; 107: 1039-47.
39. Cannarile L, Cuzzocrea S, Santucci L, et al. Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis. Gastroenterology. 2009; 136: 530-41.
40. Cohen N, Mouly E, Hamdi H, et al. GILZ expression in human dendritic cells redirects their maturation and prevents antigenspecific T lymphocyte response. Blood. 2006; 107: 2037-44.
41. Hamdi H, Godot V, Maillot MC, et al. Induction of antigen-specific regulatory t lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucin zipper. Blood. 2007; 110: 211-9.
42. +. J Am Soc Nephrol. 2003; 14: 1107-15.
43. Soundararajan R, Zhang TT, Wang J, Vandewalle A, Pearce D. A novel role for glucocorticoid-induced leucine xipper protein in epithelial sodium channel-mediated sodium transport. J Biol Chem. 2005; 280: 39970-81
44. Ayroldi E, Riccardi C, Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. Faseb J. 2009; 23: 3649-58.
45. Delfino DV, Agostini M, Spinicelli S, Vacca C and Riccardi C, Inhibited cell death, NF-B activity and increased IL-10 in TCR-triggered thymocytes of transgenic mice overexpressing the glucocorticoid-induced protein GILZ. Int Immunopharmacol. 2006; 6: 1126-34.
46. Delfino DV, Spinicelli S, Pozzesi N, et al. Glucocorticoid-induced activation of caspase-8 protects the glucocorticoid-induced protein Gilz from proteasomal degradation and induces its binding to SUMO-1 in murine thymocytes. Cell Death Differ 2011, 1: 183-90.
47. Alam SM, Davies GM, Lin CM, Zal T, Nasholds W, Redpath S, Jameson SC, Gascoigne NRJ. Qualitative and quantitative differences in T cell receptor binding of agonist and antagonist ligands. Immunity 1999, 10: 227-37.
48. Gronski MA, Boulter JM, Moskophidis D, et al. TCR affinity and negative regulation limit autoimmunity. Nat Med 2004; 10: 1234-9.
49. Davalos-Misslitz AC, Rieckenberg J, Willenzon S, et al. Generalized multi-organ autoimmunity in CCR7-deficient mice. Eur J Immunol 2007; 37: 613-22.
50. Misslitz A, Pabst O, Hintzen G, et al. Thymic T cell development and progenitor localization depend on CCR7. J Exp Med 2004; 200: 481-91.
51. Nitta T, Nitta S, Ley Y, et al. CCR7-mediated migration of developing thymocytes to the medulla is essential for negative selection to tissue-restricted antigens. Proc Natl Acad Sci USA 2009; 106: 17129-33.
52. Ueno T, Saito F, Gray DH, et al. CCR7 signals are essential for cortex-medulla migration of developing thymocytes. J Exp Med 2004; 200: 493-505.
53. Klein L, Hinterberger M, Wirnsberger G, et al. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009; 9: 833-44.
54. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the AIRE protein. Science 2002; 298: 1395-401.
55. Coutinho A, Caramalho I, Seixas E, et al. Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection. Curr Top Microbiol Immunol 2005; 293: 43-71.
56. Derbinski J, Schulte A, Kyewski B, et al. Promiscuous gene expression in thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001; 2: 1032-9.
57. Derbinski J, Pinto S, Rosch S, et al. Promiscuous gene expression patterns in single medullary thymic epithelial cells argue for a stochastic mechanism. Proc Natl Acad Sci USA 2008; 105: 657-62.
58. Gabler J, Arnold J, Kyewski B, et al. Promiscuous gene expression and the developmental dynamics of medullary thymic epithelial cells. Eur J Immunol 2007; 37: 3363-72.
59. Gillard GO, Farr AG. Features of medullary thymic epithelium implicate postnatal development in maintaining epithelial heterogeneity and tissue-restricted antigen expression. J Immunol 2006; 176: 5815-24.
60. Koble C, Kyewski B. The thymic medulla: a unique microenvironment for intracellular self-antigen transfer. J Exp Med 2009; 206: 1505-13.
61. Millet V, Naquet P, Guinamard RR. Intercellular MHC transfer between thymic epithelial cells and dendritic cells. Eur J Immunol 2008; 38: 1257-63.
62. Gray D, Abramson J, Benoist C, et al. Proliferative arrest and rapid turnover of thymic epithelial cells expressing Aire. J Exp Med 2007; 204: 2521-8.
63. The-Finnhish-German-APECED-Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. The Finnish-German APECED Consortium. Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. Nat Genet 1997, 17: 399-403.
64. Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, Krohn KJ, Lalioti MD, Mullis PE, Antonarakis SE, et al. Positional cloning of the APECED gene. Nat Genet 1997, 17: 393-8.
65. Liston A, Lesage S, Wilson J, Peltonen L, Goodnow CC. AIRE regulates negative selection of organ-specific T cells. Nat Immunol 2003; 4: 350-4.
66. Anderson MS, Venazi ES, Chen Z, Berzins SP, Benoist C, Mathis D. The cellular mechanism of AIRE control of T cell tolerance. Immunity 2005; 23: 227-39.
67. Zhu M, Chin RK, Christiansen PA, et al. NF-kappaB2 is required for the establishment of central tolerance through an AIRE-dependent pathway. J Clin Invest 2006; 116: 2964-71.
68. Kuroda N, Mitani T, Takeda N, et al. Development of autoimmunity against transcriptionally unrepressed target antigen in the thymus of AIRE-deficient mice. J Immunol 2005; 174: 1862-70.
69. Derbinski J, Gabler J, Brors B, et al. Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J Exp Med 2005; 202: 33-45.
70. Gillard GO, Farr AG. Contrasting models of promiscuous gene expression by thymic epithelium. J Exp Med 2005; 202: 15-9.
71. Gillard GO, Dooley J, Erickson M, Peltonen R, Farr AG. AIRE-dependent alterations in medullary thymic epithelium indicate a role for AIRE in thymic epithelial differentiation. J Immunol 2007; 178: 3007-15.
72. Sohn SJ, Thompson J, Winoto A. Apoptosis during negative selection of autoreactive thymocytes. Curr Op Immunol 2007; 19: 510-5
73. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994, 76: 17-27.
74. Jameson SC, Hogquist KA, Bevan MJ. Positive selection of thymocytes. Annu Rev Immunol 1995, 13: 93-126.
75. Risueno RM, van Santen HM, Alarcon B. A conformational change senses the strenght of T cell receptor-ligand interaction during thymic selection. Proc Natl Acad Sci USA 2006; 103: 9625-30.
76. Daniels MA, Teixeiro E, Gill JH et al. Thymic selection Treshold defined by compartmentalization of Ras/MAPK signalling. Nature 2006; 444: 724-9.
77. Alberolla-lla J, Takaki S, Kerner JD, Perlmutter RM. Differential signaling by lymphocyte antigen receptor. Annu Rev Immunol m1997, 15: 125-54.
78. Hogquist KA, Signal strength in thymic selection and lineage commitment. Curr Opin Immunol 2001; 13: 225-31.
79. Berg LJ, Kang J. Molecular determinants of TCR expression and selection. Curr Opin Immunol 2001; 13: 232-41.
80. Nika K, Soldani C, Salek M, et al. Constitutively active Lck kinase in T cells drives antigen receptor signal transduction. Immunity 2010; 32: 766-77.
81. Mallaun M, Naeher D, Daniels MA, et al. The T cell receptor's chain connecting peptide motif promotes close approximation of the CD8 coreceptor allowing efficient signal initiation. J Immunol 2008; 180: 8211-21.
82. Yachi PP, Ampudia J, Zal T, Gascoigne NRJ. Altered peptide ligands induce delayed and reduced CD8-TCR interaction a role for CD8 in distinguish antigen quality. Immunity 2006; 25: 203-11.
83. Gascoigne NRJ, Palmer E. Signaling in thymic selection. Curr Opin Immunol 2011, 23: 1-6.
84. Kane LP, Hedrick SM. A role for calcium influx in setting the threshold for CD4+CD8+ thymocyte negative selection. J Immunol 1996, 156: 4594-601.
85. Freedman BD, Liu QH, Somersan S, Kotlikoff MI, Punt JA. Receptor avidity and costimulation specify the intracellular Ca2+ signalling pattern in CD4(+)CD8(+) thymocytes. J Exp Med 1999, 190: 943-52.
86. Davey GM, Schober SL, Endrizzi BT, Dutcher AK, Jameson SC, Hogquist KA. Preselection thymocytes are more sensitive to T cell receptor stimulation than mature T cells. J Exp Med 1998, 188: 1867-74.
87. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2- dependent ubiquitin-protein ligase. Science 1999, 286: 309-12.
88. Liu YC. Ubiquitin ligases and the immune response. Annu Rev Immunol 2004; 22: 81-127.
89. Naramura M, Jang IK, Kole H, Huang F, Haines D, Gu H. C-Cbl and Cbl-b regulate T cell responsiveness by promoting ligandinduced TCR down-modulation. Nat Immunol 2002; 3: 1192-9.
90. Huang F, Kitaura Y, Jang I, et al. Establishment of the major compatibility complex-dependent development of CD4+ and CD8+ T cells by the Cbl family proteins. Immunity 2006; 25: 571-81.
91. Thien CB, Blystad FD, Zhan Y, et al. Loss of c-Cbl RING finger function results in high-intensity TCR signalling and thymic deletion. EMBO J 2005; 24: 3807-19.
92. Naramura M, Kole HK, Hu R-J, Gu H. Altered thymic positive selection and intracellular signal in c-Cbl-deficient mice. Proc Natl. Acad Sci USA 1998, 95: 15547-52.
93. Hoyne GF, Flening E, Yabas M, et al. Visualizing the role of Cbl-b in control of islet-reactive CD4 T cells and susceptibility to type 1 diabetes. J Immunol 2011, [Epub ahead of print]
94. Dan I, Watanabe NM, Kobayashi T, et al. Molecular cloning of MINK, a novel member of mammalian GCK family kinases, which is upregulated during postnatal mouse cerebral development. FEBS lett 2000; 469: 19-23.
95. McCarty N, Paust S, Ikizawa K, Dan I, Li X, Cantor H. Signaling by the kinase MINK is essential for the negative selection of autoreactive thymocytes. Nat Immunol 2005; 6: 65-72.
96. Sohn SJ, Rajpal A, Winoto A. Apoptosos during lymphoid development. Curr Opin Immunol 2003; 15: 209-16.
97. Kasler H, Victoria J, Duramad O, Winoto A. ERK5 is a novel type of MAP kinase containing a transcriptional activation domain. Mol Cell Biol 2000; 20: 8382-9.
98. Liston A, Hardy K, Pittelkow Y, Wilson SR, Makaroff LE, Fahrer AM, Goodnow CC. Impairment of organ-specific T cell negative selection by diabetes susceptibility genes: genomic analysis by mRNA profiling. Genome Biol 2007; 8: R12.
99. Zucchelli S, Holler P, Yamagata T, Roy M, Benoist C, Mathis D. Defective central tolerance induction in NOD mice: genomics and genetics. Immunity 2005; 22: 385-96.
100. Liston A, Lesage S, Gray DH, et al. Generalized resistance to thymic deletion in the NOD mouse; a polygenic trait characterized by defective induction of Bim. Immunity 2004; 21: 817-30.
101. Bouillet P, Purton JF, Godfrey DI, et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 2002; 415: 922-6.
102. Cheng LE, Chan FK, Cado D, Winoto A. Functional redundancy of the Nurr77 and Nor-1 orphan steroid receptors in T cell apoptosis. EMBO J 1997, 16: 1865-75.
103. Zhou T, Cheng J, Yang P, et al. Inhibition of Nurr77/Nurr1 leads to inefficient clonal deletion of self-reactive T cells. J Exp Med 1996, 183: 1879-92.
104. Calnan B, Szychowski S, Chan FKM, Cado D, Winoto A. A role of the orphan steroid receptor Nurr77 in antigen-induced negative selection. Immunity 1995, 3: 273-82.
105. Li H, Kolluri SK, Gu J, et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000; 289: 1159-64.
106. Lin B, Kolluri SK, Lin F, et al. Conversion of Bcl-2 from protection to killer by interaction with nuclear orphan receptor Nurr77/TR3. Cell 2004; 116: 527-40.
107. Wu Q, Liu S, Ye XF, Huang ZW, Su WJ. Dual roles of Nurr77 in selective regulation of apoptosis and cell cycle by TPA and ATRA in gastric cancer cells. Carcinogenesis 2002; 23: 1583-92.
108. Wilson AJ, Arango D, Mariadason JM, Heerdt BJ, Augenlicht LH. TR3/Nurr77 in colon cancer cell apoptosis. Cancer Res 2003; 63: 5401-7.
109. Lee KW, Ma L, Yan X, Liu B, Zhang XK, Cohen P. Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factorindependent nucleomitochondrial translocation of RXRalpha/Nurr77. J Biol Chem 2005; 280: 16942-8.
110. Luciano F, Krajewska M, Ortiz-Rubio P, et al. Nurr77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma. Blood 2007; 109: 3849-55.
111. Tomayko MM, Punt JA, Bolcavage JM, Levy SL, Allman DM, Cancro MP. Expression of the Bcl-2 family member A1 is developmentally regulated in T cells. Int Immunol 1999, 11: 1753-61.
112. Strasser A, Harris AW, von BH, Cory S. Positive and negative selection of T cells in T-cell receptor transgenic mice expressing a Bcl-2 transgene. Proc Natl Acad Sci USA 1994, 91: 1376-80.
113. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SL. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991, 67: 879-88.
114. Strasser A, Harris AW, Cory S. Bcl-2 transgene inhibits T cell death and perturbs thymic cell censorship. Cell 1991, 67: 889-99.
115. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
116. Schimtz I, Clayton LK, Reinherz EL. Gene expression analysis of thymocyte selection in vivo. Int Immunol 2003; 15: 1237-48.
117. Cunningham NR, Artim SC, Fornadel CM, et al. Immature CD4+CD8+ thymocytes and mature T cells regulate Nurr77 distinctly in response to TCR stimulation. J Immunol 2006; 177: 6660-6.
118. Rajpal A, Cho YA, Yelent B, et al. Transcriptional activation of known and novel apoptotic pathways by Nurr77 orphan steroid receptor. EMBO J 2003; 22: 6526-36.
119. Phillips A, Lesage S, Gingras R, et al. Novel dimeric nur77 signaling mechanism in endocrine and lymphoid cells. Mol Cell Biol 1997, 17: 5946-51.
120. Weih F, Ryseck R-P, Chen L, Bravo R. Apoptosis of nurr77/N10- transgenic thymocytes involves the Fas/Fas ligand pathway. Proc Natl Acad Sci USA 1996, 93: 5533-8.
121. Clayton LK, Ghendler Y, Mizoguchi E, et al. T-cell receptor ligation by peptide/MHC induces activation of a caspase in immature thymocytes: the molecular basis of negative selection. EMBO J 1997, 16: 2282-93.
122. Hara H, Takeda A, Takehuchi M, et al. The apoptotic proteaseactivating factor 1-mediated pathway of apoptosis is dispensable for negative selection of thymocytes. J immunol 2002; 168: 2288-95.
123. Doerfler P, Forbush KA, Perlmutter RM. Caspase enzyme activity is not essential for apoptosis during thymocyte development. J Immunol 2000; 164: 4071-9.
124. Izquierdo M; Grandien A, Criado LM, et al. Blocked negative selection of developing T cells in mice ex pressing the baculovirus p35 caspase inhibitor. EMBO J 1999, 18: 156-66.
125. Robles MS, Leonardo E, Criado LM, Izquierdo M, Martinez AC. Inhibitor of apoptosis protein from Orgyia pseudotsugata nuclear polyhedrosis virus provides a costimulatory signal requie for optimal proliferation of developing thymocytes. J Immunol 2002; 168: 1770-9.
126. Joza N, Susin SA, Daugas E, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001; 410: 549-54.
127. Li LY, Luo X, Wang X. Endonuclease G i san apoptotic DNase when released from mitochondria. Nature 2001; 412: 95-9.
128. Goodnow CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoire. Proc Natl Acad Sci USA 1996, 93: 2264-71
129. Goodnow CC, Adelstein S, Basten A. The need for central and peripheral tolerance in the B cell repertoire. Science 1990, 248: 1373-9.
130. + thymocytes. Nature 1988, 333: 742-6.
131. Nossal GJV, Pike BL. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc Natl Acad Sci USA 1980, 77: 1602-6.
132. Fierabracci A. Recent insights into the role and molecular mechanisms of the autoimmune regulator (AIRE) gene in autoimmunity. Autoimmune Rev 2011, 10: 137-43.
133. nd ed. Berlin and Heidelberg: Springer-Verlag, 1999.
134. Muller-Hermelink HK, Engel PJ, Harris NL, et al. Tumours of the thymus. In WD Travis, E Brambilla, HK Muller-Hermelink, CC Harris, eds. Tumours of the Lung, Thymus, and Heart Pathology and Genetics. Lyon: IARC Press, 2004)
135. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981, 48: 2485-92.
136. Margaritora S, Cesario A, Cusumano G, et al. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 2010; 89: 245-52; discussion 252.
137. Casey EM, Kiel PJ, Loehrer PJ Sr. Clinical management of thymoma patients. Hematol Oncol Clin North Am 2008; 22: 457-73.
138. Strobel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004; 22: 1501-9.
139. Strobel P, Helmreich M, Menioudakis G, et al. Paraneoplastic myasthenia gravis correlates with generation of mature naïve CD4+ T cells in thymomas. Blood 2002; 100: 159-66.
140. Nenninger R, Schultz A, Hoffacker V, et al. Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas. Lab Invest 1998, 78: 743-53.
141. Hoffacker V, Schultz A, Tiesinga JJ, et al. Thymomas alter the Tcell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood 2000; 96: 3872-9.
142. Buckley C, Douek D, Newsom-Davis J, et al. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 2001; 50: 64-72.
143. Strobel P, Chuang WY, Chuvpilo S, et al. Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. Ann N Y Acad Sci 2008; 1132: 143-56.
144. Marx A, Willcox N, Leite MI, et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity. In press.
145. Maclennan CA, Vincent A, Marx A, et al. Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis. J Neuroimmunol 2008; 201-202: 28-32.
146. Romi F, Bo L, Skeie GO, et al. Titin and ryanodinee receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol 2002; 128: 82-9.
147. Skeie GO, Freiburg A, Kolmerer B, et al. Titin transcripts in thymomas. Ann N Y Acad Sci 1998, 841: 422-6.
148. Chalk CH, Murray NM, Newsom-Davis J, et al. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990, 40: 1552-6.
149. Marchevsky AM, Gupta R, McKenna RJ, et al. Evidence-based pathology and the pathologic evaluation of thymomas: the World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma. Cancer 2008; 112: 2780-8.
150. Strobel P, Murumagi A, Klein R, et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type I (APS-1). J Pathol 2007; 211: 563-71.
151. Marx A, Hohenberger P, Hoffmann H, et al. The autoimmune regulator AIRE in thymoma biology. Autoimmunity and beyond. J Thorac Oncol 2010; 5: S266-S72.
152. Vincent A. Immunology of disorders of neuromuscular transmission. Acta Neurol Scand Suppl 2006; 183: 1-7.
153. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in "seronegative" myasthenia gravis. Brain 2008; 131: 1940-52.
154. Gronseth GS, Barhon RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology 2000; 55: 7-15.
155. Newsom-Davis J, Cutter G, Wolfe GI, et al. Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone. Ann N Y Acad Sci 2008; 1132: 344-7.
156. Magee MJ, Mack MJ. Surgical approaches to the thymus in patients with myasthenia gravis. Thorac Surg Clin 2009; 19: 83-9.
157. Manlulu A, Lee TW, Wan I, et al. Video-assisted thoracic surgery thymectomy for nonthymomatous myasthyenia gravis. Chest 2005; 128: 3454-60.
158. Kumar V, Kaminski HJ. Treatment of myasthenia gravis. Curr Neurol Neurosci Rep 2011, 11: 89-96.
159. WHO/UNISEF: State of the world's vaccines and immunization. Edited by: Bellamy C, Nakajima H. Geneva, World Health Organization; 1996.
160. Hilleman MR. Vaccines and vaccinations - part I. Immunol Rev 1999, 70: 7-27.
161. Jenner E. An inquiry into the causes and effects of the variolae vaccinae, a disease discovered in some Western counties of England. London: Sampson Low 1798.
162. Bouche FB, Ertl OT, Muller CP. Neutralizing B cell response in measles. Viral Immunol 2002; 15: 451-71.
163. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol 2002; 2: 706-13.
164. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991, 354: 453-9.
165. Korber B. HIV-1 intrapatient sequence diversity in the immunogenic V3 region. AIDS Res Hum Retroviruses 1992, 8: 1461-5.
166. Engers HD, Godal T. Malaria vaccine development: current status. Parasitol Today 1998, 14: 56-64.
167. Miller L, Hoffman S. Research towards vaccines against malaria. Nature Med 1998, 4: 520-4.
168. Sasada T, Ghendler Y, Wang JH, Reinherz EL. Thymic selection is influenced by subtle structural variation involving the p4 residue of an MHC class I-bound peptide. Eur J Immunol 2000; 30: 1281-9.
169. Fridkis-Hareli M, Reinherz EL. New approaches to eliciting protective immunity through T cell repertoire manipulation: the concept of thymic vaccination. Med Immunol 2004; 3: 2.